Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prodiol cannabinoids
- Development stage
- Preclinical
- Lead developer
- BayMedica
- Modality
- Small Molecules
- Administration
- Oral, Topical, Ophthalmic
01
Overview
Prodiol cannabinoids refer to a pipeline of rare cannabinoid analogs and bio-identical compounds developed by BayMedica, a subsidiary of InMed Pharmaceuticals. The Prodiol line is centered around cannabidiol (CBD) and its structural derivatives, produced using a proprietary hybrid synthetic biology and chemistry platform. These small molecules are designed to interact with the endocannabinoid system and related pathways, such as TRP channels and G-protein coupled receptors, to address various therapeutic areas including inflammatory diseases and neurological disorders. The "Additional Prodiol cannabinoids" entry in the company's pipeline represents a collection of these derivatives currently in preclinical development.
- Brand names
- Prodiol
- Other names
- BayMedica cannabinoids
02
Targets
CNR1 (Cannabinoid receptor 1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on prodiol cannabinoids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prodiol cannabinoids.